|
|
Anti-hypertensives: Landmark clinical trial update - Commercial assessment of CHARM, COMET, EPHESUS and EUROPAPublished by: Datamonitor Published: Nov. 3, 2003 - 48 Pages Table of ContentsTABLE OF CONTENTS EXECUTIVE SUMMARY 5 Introduction 5 Scope and coverage of the brief 5 Key findings about the topic 6 CHAPTER 1 CHARM: CANDESARTAN IN HEART FAILURE 8 Background 8 Study objectives and design 9 Results 11 CHARM Alternative 11 CHARM Added 12 CHARM Preserved 13 Overall CHARM program 14 Commercial implications 15 Candesartan forecasts 17 CHAPTER 2 COMET: CARVEDILOL VS. METOPROLOL IN HEART FAILURE 19 Background 19 Carvedilol 20 Bisoprolol 20 Metoprolol 21 Carvedilol vs. metoprolol in heart failure 21 Study objectives and design 21 Expectations 22 Results 23 Controversy over dose and formulation of metoprolol 24 Commercial implications 25 Carvedilol and metoprolol forecasts 27 CHAPTER 3 EPHESUS: EPLERENONE IN HEART FAILURE 29 Background 29 Study objectives and design 29 Results 31 Commercial implications 32 Inspra (eplerenone) forecasts 33 CHAPTER 4 EUROPA: PERINDOPRIL IN CORONARY ARTERY DISEASE 35 Background - the ‘HOPE’ effect 35 Study objectives and design 36 Results 38 Commercial Implications 39 Perindopril forecasts 40 CHAPTER 5 CONCLUSIONS 42 CHAPTER 6 APPENDIX 46 AbstractIntroductionSeveral landmark clinical trials studying the benefits of anti-hypertensives beyond blood pressure control have recently been reported. CHARM, COMET and EPHESUS focused on heart failure, where unmet need remains extremely high. EUROPA, looked at the coronary artery disease population to assess whether the benefits of ramipril in HOPE also apply to another ACE inhibitor in lower-risk patients. Scope * Provides a critical analysis of the commercial impact of these trials, along with updated sales forecasts to 2011 for the drugs concerned. * Assesses the potential for ARBs and eplerenone in heart failure and the factors that will limit their uptake despite the CHARM and EPHESUS results? * Evaluates the robustness are the COMET results and the extent to which physicians using metoprolol in heart failure will now switch to carvedilol? * Discusses whether EUROPA will dramatically expand the use of ACE inhibitors and the market implications of the trial for perindopril and ramipril? Report Highlights Development for additional indications has been the key means of expanding the patient potential of anti-hypertensives and has become a prerequisite for success in this highly competitive market. CHARM, COMET, EPHESUS and EUROPA will have a significant impact on the market, driving overall growth and increasing the market share of the study drugs. Datamonitor forecasts that total sales of the four main drugs in these trials will grow from $2.6 billion in 2002 to $10.9 billion in 2010. Reasons to Purchase * Understand the importance of the CHARM, COMET, EPHESUS and EUROPA trials and effectively anticipate their impact on the anti-hypertensives market. * Identify the factors that may constrain the uptake of these drugs in the trial indications studied. * Access updated forecasts to 2011 for the key drugs involved in these trials Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||